The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.
NCT ID: NCT01996540
Last Updated: 2018-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
394 participants
INTERVENTIONAL
2012-08-31
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Description of Study Treatment:
1. Interventional arm Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death. Patients assigned to this experimental arm will be evaluated if the total of palliative care visits between T0 (day of enrollment) and T1 (12±3 weeks) is ≥3. Palliative care visits and intervention has to be oriented by the General guidelines for palliative care: specific attention will be paid to assessing physical and psychosocial symptoms, establishing goals of care, assisting decision making regarding treatment, and coordinating care on the basis of the individual needs of the patients.
The doctor expert in palliative care, with regular visits in the experimental arm, must be a physician dedicated full time to palliative care, that can directly prescribe drugs and other interventions, and with a particular attention to physical, psychological, and spiritual needs.
Palliative care doctor must have the possibility to decide about organizational arrangements.
He has to perform the palliative care visit according to Temel indications.
2. Standard arm Patients will receive standard oncologic care and will be assigned to on request palliative care consultation. They will be not scheduled to meet with the palliative care service unless a meeting will be requested by the patients, the family, or the oncologist. After the time of evaluation (T1) patients will be followed by the palliative care services as needed.
Patient completes QoL (Quality of Life) and mood questionnaires at baseline and at 12 weeks ± 3.
Patients will receive standard antineoplastic treatment in both arms of the study according to best clinical practice in each participating centre.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
NCT02307539
Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient
NCT06090825
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
NCT00813696
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
NCT05181605
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Short Title/Acronym: Early palliative care
Protocol Code: IRST 100.08
Study Design: randomized, controlled, multicenter trial
Study Duration: 2 years
Number of Subjects: 240
Description of Study Treatment:
1. Interventional arm Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death. Patients assigned to this experimental arm will be evaluated if the total of palliative care visits between T0 (day of enrollment) and T1 (12±3 weeks) is ≥3. Palliative care visits and intervention has to be oriented by the General guidelines for palliative care: specific attention will be paid to assessing physical and psychosocial symptoms, establishing goals of care, assisting decision making regarding treatment, and coordinating care on the basis of the individual needs of the patients.
The doctor expert in palliative care, with regular visits in the experimental arm, must be a physician dedicated full time to palliative care, that can directly prescribe drugs and other interventions, and with a particular attention to physical, psychological, and spiritual needs.
Palliative care doctor must have the possibility to decide about organizational arrangements.
He has to perform the palliative care visit according to Temel indications.
2. Standard arm Patients will receive standard oncologic care and will be assigned to on request palliative care consultation. They will be not scheduled to meet with the palliative care service unless a meeting will be requested by the patients, the family, or the oncologist. After the time of evaluation (T1) patients will be followed by the palliative care services as needed.
Patient completes QoL (Quality of Life) and mood questionnaires at baseline and at 12 weeks ± 3.
Patients will receive standard antineoplastic treatment in both arms of the study according to best clinical practice in each participating centre.
Primary Objective:
To assess the effects on quality of life and clinical symptoms of introducing early systematic palliative care versus on request palliative care consultation during standard oncological care on quality of life.
Secondary Objectives:
* To assess the impact of early palliative care on symptom burden and mood.
* To assess the impact of families satisfaction about care.
* To compare the use of health services, including anticancer therapy, medication prescriptions, referral to hospice, hospital admissions, emergency department visits, and the location of death between study arms.
* To compare overall survival.
Statistical Methodology:
Primary endpoint is the change in the score from T0 to T1 on the Trial Outcome Index (TOI), which is the sum of the scores of specific subscale FACT-Ga or FACT-Hep concerning physical symptoms, and physical and functional well being.
Secondary endpoints are the change in the percentage of patients with anxiety and/or depression form T0 to T1 on the Mood questionnaire; the impact of families satisfaction about care; the use of health services, including anticancer therapy, medication prescriptions, referral to hospice, hospital admissions, emergency department visits, and the location of death between study arms; the overall survival.
For each type of cancer (gastric or pancreatic), we estimate that with 120 patients the study would have 80% power to detect a significant between-group difference in the change in the TOI score from T0 to T1, with a medium effect size of 0.5 standard deviation. A total of 240 patients will be enrolled.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional arm
Interventional arm
Interventional arm: Early best palliative care
Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
Standard arm
Standard arm
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interventional arm: Early best palliative care
Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. patients eligible for chemotherapy and/or new target drugs treatments for metastatic or advanced disease;
3. ECOG PS 0-2 (Appendix A);
4. life expectancy \>2 months;
5. both sex;
6. age ≥18 years;
7. all ethnic background;
8. subjects who are, in the opinion of the Investigator, able to understand this study and to cooperate with the study procedures;
9. written informed consent (Appendix B);
10. palliative care visit must be performed by a dedicated physician/team different from the medical oncology group.
Exclusion Criteria
2. prior chemotherapy and/or new target drugs treatments for metastatic or advanced disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Maltoni, MD
Role: PRINCIPAL_INVESTIGATOR
IRST IRCCS, Meldola
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palliative Care Clinic IRCCS IRST
Meldola, FC, Italy
U.O Oncologia medica
Lugo, RA, Italy
S. Donato, Arezzo
Arezzo, , Italy
Centro di Riferimento Oncologico CRO
Aviano, , Italy
Ospedale degli Infermi,
Biella, , Italy
Ospedale Businco, Cagliari
Cagliari, , Italy
Policlinico Universitario, Cagliari
Cagliari, , Italy
ASL AL, Casale Monferrato
Casale Monferrato, , Italy
Irst-Cesena
Cesena, , Italy
Sant'Anna
Como, , Italy
PO M.Santo, Cosenza
Cosenza, , Italy
Istituti Ospitalieri, Cremona
Cremona, , Italy
Sant'Anna, Ferrara
Ferrara, , Italy
S.Giovanni Di Dio, Firenze
Florence, , Italy
S.Maria Annunziata,
Florence, , Italy
E.O. Galliera
Genova, , Italy
Aulss 12,
Mestre, , Italy
Istituto Nazionale Tumori, Milano
Milan, , Italy
Ospedale Sacco, Milano
Milan, , Italy
S.PAOLO
Milan, , Italy
IOV
Padua, , Italy
San Matteo
Pavia, , Italy
Guglielmo da Saliceto
Piacenza, , Italy
Arcispedale S. Maria Nuova
Reggio Emilia, , Italy
Fatebenefratelli,
Roma, , Italy
SS Trinità,
Sora - Frosinone, , Italy
Gradinego
Torino, , Italy
AOP 9, Trapani
Trapani, , Italy
S. Maria Gruccia, Valdarno
Valdarno, , Italy
AULSS 12, Venezia
Venezia, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Scarpi E, Dall'Agata M, Zagonel V, Gamucci T, Berte R, Sansoni E, Amaducci E, Broglia CM, Alquati S, Garetto F, Schiavon S, Quadrini S, Orlandi E, Casadei Gardini A, Ruscelli S, Ferrari D, Pino MS, Bortolussi R, Negri F, Stragliotto S, Narducci F, Valgiusti M, Farolfi A, Nanni O, Rossi R, Maltoni M; Early Palliative Care Italian Study Group (EPCISG). Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. Support Care Cancer. 2019 Jul;27(7):2425-2434. doi: 10.1007/s00520-018-4517-2. Epub 2018 Oct 24.
Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codeca C, Broglia CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A, Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D, Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O; Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016 Dec;69:110-118. doi: 10.1016/j.ejca.2016.10.004. Epub 2016 Nov 4.
Maltoni M, Scarpi E, Dall'Agata M, Zagonel V, Berte R, Ferrari D, Broglia CM, Bortolussi R, Trentin L, Valgiusti M, Pini S, Farolfi A, Casadei Gardini A, Nanni O, Amadori D; Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. Eur J Cancer. 2016 Sep;65:61-8. doi: 10.1016/j.ejca.2016.06.007. Epub 2016 Jul 26.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: study publication
Maltoni M et al Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. Eur J Cancer 2016 Sep;65:61-8
View DocumentDocument Type: study publication
Maltoni M et al Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer 2016 Dec;69:110-118.
View DocumentDocument Type: study publication
Scarpi E. et al Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes
View DocumentOther Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRST100.08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.